Geranyl Geranyl Aceton (GGA) decreases Atrial Fibrillation (Trial)
Atrial Fibrillation is the most common – age related – heart disease and can cause serious complications such as heart failure and a stroke. Each year, 20,000 patients get diagnosed with Atrial Fibrillation in the Netherlands and this number is still rising. 30% of patients who get treated with an open heart surgery develop Atrial Fibrillation.
Atrial Fibrillation changes over time from short-term attacks to a heart rhythm disorder that persists permanently. This is caused by Atrial Fibrillation inducing electrical and structural changes (“electro-pathology”) in the atria.
Atrial Fibrillation treatment
Several treatments have been used to treat Atrial Fibrillation. However, none of these treatments are focused on ‘curing’ Atrial Fibrillation.
Recent results by our research group have shown that drugs that stimulate cardioprotective proteins within heart cells (i.e. Heat Shock Proteins (HSP)) prevent Atrial Fibrillation within animal models.
GGA is a compound stimulating the development of HSPs within the heart. The compound is not toxic and has been around on the Asian market since 1984.
Striking GGA results:
- GGA administration helps to prevent Atrial Fibrillation in dogs.
- A 3-day oral treatment with 400 mg GGA increases protected HSP levels in the atrial tissue.
However, we do not know yet whether GGA administration in patients can prevent someone’s chance to develop Atrial Fibrillation and accelerate recovery from Atrial Fibrillation.
GGA Research Project Request
Within this research request we want to study whether administration of GGA:
- Increases HSP values within heart muscle tissue
- Decreases the probability of ‘new’ AF development after open heart surgery
Additionally, we want to study whether age or gender related effects of GGA on electropathology exist through quantification of:
- Structural remodeling (test for correlation of biomarkers within atrial tissue and blood)
- Electrical remodeling (measuring level of arrhythmogenic signals through epicardial, high resolution mapping)
- Measure the frequency and length of AF episodes (AF burden)
Positive results of our first therapeutic study, focused on the recovery of the atrial heart muscle cell and thereby resulting in a reduction in AF burden, will be a true breakthrough in the treatment of patients suffering from Atrial Fibrillation.